TY  - JOUR
AU  - Salvador Martín, Sara
AU  - Kaczmarczyk, Bartosz
AU  - Alvarez, Rebeca
AU  - Navas López, Víctor Manuel
AU  - Gallego Fernández, Carmen
AU  - Moreno Álvarez, Ana
AU  - Solar Boga, Alfonso
AU  - Sánchez Sánchez, César
AU  - Tolin, Mar
AU  - Velasco, Marta
AU  - Muñoz Codoceo, Rosana
AU  - Rodriguez Martinez, Alejandro
AU  - Vayo, Concepción A.
AU  - Bossacoma, Ferrán
AU  - Pujol Muncunill, Gemma
AU  - Fobelo, María J.
AU  - Millán Jiménez, Antonio
AU  - Magallares, Lorena
AU  - Martínez Ojinaga, Eva
AU  - Loverdos, Inés
AU  - Eizaguirre, Francisco J.
AU  - Blanca García, José A.
AU  - Clemente, Susana
AU  - García Romero, Ruth
AU  - Merino Bohórquez, Vicente
AU  - González de Caldas, Rafael
AU  - Vázquez, Enrique
AU  - Dopazo, Ana
AU  - Sanjurjo Sáez, María
AU  - López Fernández, Luis Andrés
PY  - 2021
DO  - 10.3390/pharmaceutics13010077
SN  - 1999-4923
UR  - https://hdl.handle.net/20.500.14352/7427
T2  - Pharmaceutics
AB  - Background: Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF...
LA  - eng
M2  - 77
PB  - MDPI
KW  - Biomarker
KW  - Gene expression
KW  - Infliximab
KW  - Adalimumab
KW  - Ulcerative colitis
KW  - Crohn disease
KW  - Inflammatory bowel disease
TI  - Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
TY  - journal article
VL  - 13
ER  -